# Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study

> **NCT05873790** · — · UNKNOWN · sponsor: **The First Hospital of Jilin University** · enrollment: 30 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Serplulimab plus chemotherapy

## Key facts

- **NCT ID:** NCT05873790
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05873790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05873790, "Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05873790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*